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Introduction
Perfluorocarbon emulsions (PFCs) are a small volume robust (temperature stable, long storage life, portable) intravenous (i.v.) fluid, easily carried by medics/corpsmen to site of first contact. PFCs enhance O2 solubility/diffusion from circulating red cells. PFCs have shown efficacy in animal models of hemorrhagic shock, tissue ischemia, decompression sickness (DCS), traumatic brain injury (TBI) and other important military applications. Our work and that of others demonstrated that PFCs enhance O2 delivery at normal FiO2 and that perhaps the most important aspect of PFC infusion was an enhanced O2 delivery from native erythrocytes to tissues. Furthermore, it appears that PFCs enhance O2 diffusion, thereby decreasing the barrier to non-polar gas movement made up of aqueous materials (plasma and extracellular fluids). However, a class-based side effect of PFC (day 2-5 after infusion in 30-50%) is thrombocytopenia (TCYP). The mechanism is inadequately investigated but is caused by reduced production or enhanced clearance (partial activation) of platelets (Plts). These safety concerns posed by the United States Food and Drug Administration (FDA) have to do with a potential risk of hemorrhage/thrombosis and inflammation related to PFC infusion. Casualty care for hemorrhage, gas embolism (blast and DCS) and TBI all involve degrees of inflammatory up-regulation and variable elements of coagulopathy. The current approved work is to answer safety and mechanism questions regarding causes/extent of thrombocytopenia after PFC infusion. Pertinent large animal models of normal and casualty scenarios will be investigated, thereby demonstrating whether the use of PFC in hemorrhage and blast TBI possess any added coagulopathic risk to future victims, compared to normal. Large animal models will examine specific causal hypotheses for TCYP and whether this exists as a class effect. In the end, the work will provide answers to questions blocking further development of PFCs. In this proposed study, the side effects of two PFC's on platelet count, structure and function will be tested. PHER-O2 contains perfluorodecalin (88%), purified water and an emulsifier that allows the product to be administered intravenously. Perfluorodecalin is a biologically inert substance that is not metabolized by the body but rather is excreted from the body through normal respiration. Oxygent, another resuscitation product, contains perflubron emulsion (60%, w/v) and has a similar O2 carrying capacity like PHER-O2. In the present study, the specific aims are to answer the following: #1 Whether PFC infusion activates Plts in vivo, #2 Whether Plt/white cells clumps (microaggregates) occur, and #3 Evaluate the mechanisms of partial Plt activation (if it occurs).
Body of Report Material and Methods:
All animals received humane care in compliance with the "Eighth Guide for Care and Use of Laboratory Animals", prepared by the National Academy of Sciences and published by the National Institutes of Health. This study was approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AALAC) certified Virginia Commonwealth University Institutional Animal Care and Use Committee (IACUC) and was also approved by the USAMRMC Animal Care and Use Review Office (ACURO).
Study Design:
A randomized ovine (20-30 kg) normal animal model was used. Animals were anesthetized, instrumented and had either hetastarch or an equal volume of one of three commercially available PFCs administered. At key time points blood samples were tested for Plt/white cell activation and morphology (Plt number, Plt white cell aggregates, flow cytometry-glycoprotein expression) as well as other coagulation data ( RoTEM, Platelet Shear Modulus, PFA-100 and Plt aggregometry) and compliment expression. Samples were examined with scanning electron microscopy for Plt and white cell transmission. In years 2-3 the ovine studies will turn to a polytrauma model of combined hemorrhagic shock and blast TBI. Volume resuscitation will occur with either hetastarch or PFC. Similar studies of Plt and white cell activation will be carried out.
Subjects:
When Juvenile sheep (Dorset/Dorper cross, 25-30 kg) were shipped to VCU DAR facility, general health checkup was taken immediately by a veterinarian, including measurements of sheep body temperature, heart rate and respiratory auscultation. Venous blood sample were drawn for complete blood count (CBC). Stool samples were examined for any parasite infections. Sheep were acclimated for 7 days in order to recover from shipping fever or to treat any potential infection. Sheep were randomized into one of three groups: PFC (Oxygent) group; Hetastarch (Hespan) group and Naïve or saline control group. In 2013, 26 sheep were shipped to VCU DAR facility. 3 sheep were used for topload or hemorrhagic shock model development. 4 sheep were sick and were excluded from the study based on veterinarian advice. 19 animals were used for the study as follows: Oxygent group, n=7; Hespan group, n=6 and control group, n=6.
Animal procedures: Coagulopathy in sheep top loaded with PFC or hetastarch was assesed at baseline prior to compound administration and at time zero, 3 hours, 1 day, 4 days, and 7 days following infusion. Baseline venous samples via external jugular vein puncture were taken two days before topload experiments. On procedure day, sheep were anesthetized with 4~5% isoflurane via vaporizer cart. Once unconscious, anesthesia was maintained with 2~3% isoflurane based on the anesthesia level assessment. Animals were transported to laboratory. Then, the animals were intubated and ventilated with mixed 70% nitrogen : 30% oxygen. The animal's neck area was shaved and disinfected with 70% ethanol and betadine as well as covered with a surgical drape. Local lidocaine was used to reduce pain. A jugular needle catheter (20 Gauge, 2 inch in length) was placed for PFC or Hespan infusion (3g/kg) over 15 minutes. Immediately following infusion, time zero blood sample was collected. The jugular catheter was removed and the puncture site sanitized. The initial top-load procedure was about 20~40 minutes. There was no dehydration during this short period. During the procedure, body temperature was maintained with pre-warmed heating blanket. Animal's heart rate and oxygen saturation were monitored. The animal was then transported back to DAR vivarium for recovery from anesthesia. Animals were monitored and weighed on a daily basis to ensure proper food intake and hydration. Note that animal venous blood was sampled via jugular vein puncture for baseline, 3 hours after top-load, 24 hours, 4 days and 7 days post top-load without anesthesia. Blood sampling without anesthesia is a common veterinary practice and minimizes respiratory distress and the potential for decreased food intake and dehydration from repetitive daily exposure to gas anesthesia.
Study endpoints: 1. Sheep behavioral monitoring was entirely observational and the sheep were in their own enclosure with the rest of their flock during the period of observation. Video cameras were used to monitor the sheep 24/7 before and after experiments. Scoring of the video records was done by an observer who was blind to the treatment status of the sheep in question and was scored based on the proportion of each day that the sheep spends actively moving around the enclosure, feeding, or lying down and inactive. After the conclusion of the experiment all animals were humanely euthanized. Sheep were video monitored from 2 days before top load through 7 days after the experiment. Screen monitoring and video record materials are protected and accessed only by authorized personnel following IACUC guide lines. 2. Blood sample analyses included coagulopathy tests (see attached assay protocol); platelet count, blood biochemistry and platelet morphologic observation using scanning electron microscopy.
Statistical analysis:
Power analysis based on sheep platelet mean number was used to estimate animal numbers per experimental group. JMP pro 10.0 statistical software was used to analyze all blood sample results. Data distribution and one-way analysis of variance (ANOVA) were used to compare means. Data was compared among groups and within the group at different time points. Significant difference between means was p value less than 0.05 (p<0.05).
Results (blood sample analyses)
1. Platelet count Normal sheep platelet mean value was about 400,000 (range from 100,000 to 800,000). Our study data showed that platelet count did not change significantly when compared with control and Hespan groups. Oxygen group, n=7; Hespan group, n=6; Naïve/saline group, n=6 4b Clot formation time (Intem) measurement: There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05).
4c Clot formation time (Natem) measurement: There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05). 5a Clotting time Extem measurement: There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05).
5b Clotting time Intem measurement: There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05).
5c Clotting time Natem measurement: There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05). 
Collagen Aggregation
There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05).
ADP Aggregation
CD62p
There was no significant difference when groups were compared after top-load with Oxygent or Hespan. Also, no significant difference was found within the groups when different time points were compared (p>0.05). 
Alanine Aminotransferase Level
There was no significant difference when groups were compared after top-load at baseline, 0 and 3 hour point. However, after 24 hours, ALT had a trend to increase (p=0.062) in control group. Also, ALT was significantly increased at 24 hours and 4 days after top-load with Oxygent (p<0.0003) or Hespan (p<0.0151) compared with baseline.
Results (sheep behavioral monitoring)
All sheep subjected to blood sample analyses outlined above were observed behaviorally using noninterfering video camera to hard drive recording from 2 days prior to top-load procedure through the duration of the blood sample time points. Data is currently being analyzed and will be revealed in future reports.
Result summary:
In the current study period, healthy sheep received intravenous infusion of Oxygent PFC, hestastarch, or saline/control. PFC animals showed no significant reduction of platelet count nor revealed significant activation of platelets when compared with control groups or compared with its baseline. More detailed data analysis is ongoing. Based on the original plan, each group needs 8 to 11 cases to reduce the data standard deviation.
Problems and solutions:
1. One PFC (Oxygent) has been tested and a second PFC used previously in blast TBI studies (PHER-O2) has not been delivered. Solution: The third PFC, "Perforan" was recently delivered and will be tested and compared with Oxygent.
2. Platelet functional assay: there were a few number of data drift away from baseline without clear reason. Solution: Sample values were doubled and repeatedly measured.
3. Sheep health is very important for the study. When there were sick sheep, it was difficult to distinguish ill sheep from PFC's side effect. We had lost 4 sheep in early summer time. Solution: Meeting with DAR veterinarians resulted in the vendor treating sheep with antibiotics before shipping and acclimation time post shipping was extenede from 3 days to 7 days. 3. The large animal survival hemorrhagic shock and trauma model has been established.
4. Manuscripts and abstracts are being developed based on the results of the current study.
5. Current study budget supports 3 full time employee and two part time employees.
Conclusion for year one:
1. Intravenous PFC infusion in healthy sheep did not significantly reduce platelet number. Functional assays did not show significant activation of platelet and white blood cells by either functional tests or by scanning EM.
2. These results suggest that further study of PFC is warranted as planned. This research project going forward is to assess whether the addition of PFC in the face of hemorrhagic shock increases the coagulopathy of shock and eventually in the combination of hemorrhagic shock plus blast traumatic brain injury.
3. Expanded experiments using PFCs other than Oxygent will continue for comparison and these data will be made available to the public (peer reviewed publications) as well as to manufacturer's of PFC so that approaches to the FDA for further clinical trials can be established.
4. At this time, independent activation of platelet's or white cells by Oxygent (our only tested PFC in this model for this reporting period) was not observed.
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